Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Single Agent Rasburicase in Treatment/Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Adult and Pediatric Patients With Lymphoma/Leukemia/Solid Tumor Malignancies at Their First Relapse or Refractory Disease

NCT00230217 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00230217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00230217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Single Agent Rasburicase in Treatment/Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Adult and Pediatric Patients With Lymphoma/Leukemia/Solid Tumor Malignancies at Their First Relapse or Refractory Disease
Lead sponsor
Sanofi
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2004
Completion date
July 31, 2006
Enrollment
94 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

hyperuricemia, tumor lysis syndrome, tumors